Keep the faith11 Jun 2025 14:54
Oxford BioMedica PLC, up 1.7% at 339.25p, 12-month range 232.50p-455.00p. The cell and gene therapy contract development and manufacturing organisation hails "strong commercial momentum" during the first half of the year, in an update ahead of its annual general meeting this afternoon. Chief Executive Officer Frank Mathias says: "The company reiterates its financial guidance today and remains focused on supporting clients across all stages of development. OXB remains confident in its near and medium-term targets as set out earlier this year." Back in April, it forecast compound annual revenue growth of over 35% for the 2023-2026 period, as well as a "pivot to profitability" in 2025.